SVRA · Savara, Inc.
$5.75
-3.65% last session
End-of-day data · updated 2026-07-25
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-18.7
Dividend yield
—
Beta
0.24
Avg volume
2M
Employees
0K
2D change
-4.17%
5D change
0.36%
10D change
-5.16%
30D change
-8.62%
60D change
7.20%
MTD change
-9.08%
YTD change
-8.62%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — SVRA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2025-12-23
Latest call per bank · past 12 months
Wells Fargo
Overweight$9.00
+56.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2025-12-23 | HC Wainwright & Co. | Maintains | Buy | $8.00 → $10.00 |
| 2025-12-18 | Wells Fargo | Maintains | Overweight | $7.00 → $9.00 |
| 2025-11-14 | Oppenheimer | Maintains | Outperform | $8.00 → $9.00 |
| 2025-11-13 | Citizens | Maintains | Market Outperform | $11.00 → $10.00 |
| 2025-10-23 | JMP Securities | Maintains | Market Outperform | $8.00 → $11.00 |
| 2025-09-09 | Guggenheim | Maintains | Buy | $8.00 → $11.00 |
| 2025-09-08 | Oppenheimer | Maintains | Outperform | $6.00 → $8.00 |
| 2025-09-03 | HC Wainwright & Co. | Maintains | Buy | $5.00 → $8.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-27
- RSI (14): RSI is 45 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 0.5% above the 50-day MA ($5.51).
- Price vs 200-day MA: Trading 3.4% above the 200-day MA ($5.36).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.06) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($2.55) and high ($6.94).
SVRA Price Chart
Loading chart for SVRA…
Fundamentals
About Savara, Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$121B 5.3% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$69B -14.8% YTD
ARGX
argenx SE
$57B 9.2% YTD
RVMD
Revolution Medicines, Inc.
$40B 137.6% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$36B -31.7% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.7% YTD
ROIV
Roivant Sciences Ltd.
$25B 61.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.